key: cord-0738496-b5o3to1j authors: Knoop, Andre; Geyer, Hans; Lerch, Oliver; Rubio, Ana; Schrader, Yvonne; Thevis, Mario title: Detection of anti‐SARS‐CoV‐2 antibodies in dried blood spots utilizing manual or automated spot extraction and electrochemiluminescence immunoassay (ECLIA) date: 2021-03-26 journal: Analytical science advances DOI: 10.1002/ansa.202100009 sha: 806960a25b1ea761b5ffa8ed9a63ebda7a1eb0a1 doc_id: 738496 cord_uid: b5o3to1j Serological test methods to detect anti‐SARS‐CoV‐2 antibodies represent a major measure to manage the pandemic caused by the coronavirus disease 2019 (COVID‐19). In this communication, test results obtained from minimal‐invasively collected dried blood spot (DBS) specimens, which can be sampled ‘at home’ without the need of medically trained personnel, are compared to conventionally collected venous blood samples. DBS samples were prepared for analysis either manually or by a card extraction robot, and electrochemiluminescence assay (ECLIA) characteristics, assay readout values as well as stability data covering a period of more than 200 days are provided. Constant anti‐SARS‐CoV‐2 antibody readouts of quality control DBS were obtained over the entire test period using DBS specimens stored under dry and dark conditions. In addition, test results obtained from individuals tested twice within 10 months post‐infection indicated a consistent presence of antibodies. To date, various analytical testing procedures are approved and available, including molecular antigen detection (nucleic acid tests, NAT) as well as a versatile range of serological tests (antibody detection). 12 NAT approaches, especially the promptly developed real-time reverse-transcription-polymerase chain reaction (RT-PCR) assay 13, 14 are the gold standard for confirming a SARS-CoV-2 infection. In addition, rapid test methods such as lateral flow immunoassays (LFIA) have been introduced for various purposes, e.g. for access control to sensitive areas. 15 Serum and plasma were prepared by centrifugation (1800 × g, 5 min) from venous whole blood collection tubes and were immediately appli- Alternatively To prevent dilution effects, the volume is pushed throughout the system and the card material by injection of air instead of other solvents or water. Immediately before passing the sample spot, the flow is reduced to 250 µL/min and the EDTA solution is heated to approximately 80 • C by a built-in preheater before entering the clamp mechanism (step 2). The extract is transferred via the sideport-syringe of the right MPS to open vials (step 3). This procedure is followed by washing steps (step 4 and 5) with the EDTA solution and drying of the system by finally injecting air (step 6). The extraction protocol is summarized in Table 1 . After desorption, washing and drying, another photo of the card is taken for quality control and documentation purposes, before the card is returned to the respective rack position. Due to the requirements of undiluted extraction the overall extraction time per spot is approximately 7 min. Assays accepting more dilute extracts will be compatible with simplified extraction protocols allowing for reduced runtimes of approximately 3 min per DBS. For the detection of anti-SARS-CoV-2 antibodies, a Cobas e411 analyzer for immunoassay testing (Roche Diagnostics GmbH, Mannheim, Germany) was applied, using an ECLIA Elecsys Anti-SARS-CoV-2 (REF Assay characterization According to the manufacturer's instruction leaflet, 28 In the context of a pilot study, more than 500 DBS samples, collected Table 3 . Being considered as qualitative information only, the obtained data corroborate the long-term presence of anti-SARS-CoV-2 antibodies. Finally, the ELICA readouts of manually prepared rDBS QC samples were compared to extracts of the same sample handled by the DBS-A robot. As depicted in Figure 6 , an average recovery of 57% was enabled by the DBS-A automated extraction when compared to the manual sample preparation protocol. Values were found to be well correlated despite the consistently lower recovery found for automated extraction. Besides routine preventive maintenance (every 6-12 months) of the The authors acknowledge support from the Federal Ministry of the Interior, Building and Community (Berlin, Germany), the Manfred-Donike-Institute for Doping Analysis (Cologne, Germany), and Dr. Thomas Piper. The data that support the findings of this study are available from the corresponding author upon reasonable request. Oliver Lerch is an employee of Gerstel GmbH & Co. KG. Andre Knoop https://orcid.org/0000-0003-0040-8754 A novel coronavirus from patients with pneumonia in China A pneumonia outbreak associated with a new coronavirus of probable bat origin COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses EMA recommends first COVID-19 vaccine for authorisation in the EU US Food&Drug Administration. Pfizer-BioNTech COVID-19 Vaccine EMA recommends COVID-19 Vaccine Moderna for authorization in the EU EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU PHE investigating a novel variant of COVID-19 Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. medRxiv Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv The role of antibody testing for SARS-CoV-2: is there one? Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens Laboratory testing methods for novel Severe Acute Respiratory Syndrome-Coronavirus-2 Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): current status, challenges, and countermeasures SARS-CoV-2 antibody testing-questions to be asked EXPRESS: development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens Fully automated dried blood spot sample handling and extraction for serological testing of SARS-CoV-2 antibodies High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay Sensitive detection of SARS-CoV-2-specific antibodies in dried blood spot samples Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2 antibody tests Little to give, much to gain-what can you do with a dried blood spot The application of fully automated dried blood spot analysis for liquid chromatography-tandem mass spectrometry using the CAMAG DBS-MS 500 autosampler Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS Elecsys Anti-SARS-CoV-2: Immunoassay for the qualitative detection of antibodies against SARS-CoV-2 Detection of anti-SARS-CoV-2 antibodies in dried blood spots utilizing manual or automated spot extraction and electrochemiluminescence immunoassay (ECLIA)